A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer

British Journal of Cancer

Volumn 92, Issue 7, 2005, Pages 1261-1267

  Bussolati, G ^a   Montemurro, F ^b   Righi, L ^a   Donadio, M ^c   Aglietta, M ^b   Sapino, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

Biotin; Breast carcinoma; HER 2; Predictivity; Trastuzumab

Indexed keywords

BIOTHER; BIOTIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORSERADISH PEROXIDASE; MONOCLONAL ANTIBODY; NAVELBINE; STREPTAVIDIN; TRASTUZUMAB; TRASTUZUMAB BIOTINAMIDE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ADVANCED CANCER; AGED; ANTIBODY SPECIFICITY; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; BIOTINYLATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CELL MEMBRANE; CHEMICAL LABELING; COMPLEX FORMATION; CONJUGATE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG BINDING SITE; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; ONCOGENE NEU; OUTCOMES RESEARCH; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RELIABILITY; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; TUMOR CELL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BIOTINYLATION; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOASSAY; IN SITU HYBRIDIZATION; INDICATORS AND REAGENTS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RISK FACTORS; STREPTAVIDIN; TREATMENT OUTCOME;

EID: 18044392064     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602507     Document Type: Article

References (29)

1. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER-2 antibody (Herceptin) enhances the antitumour activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831
2. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G, van de Vijver M (2003) Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 16: 173-182
3. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21: 283-290
4. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289
5. Ceccarelli C, Santini D, Gamberini M, Taffurelli M, Chieco P, Piana S, Pileri S, Marrano D (1999) Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer. Breast Cancer Res Treat 58: 107-114
6. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney Jr DW, Leahy DJ (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 42I: 756-760
7. 2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58: 5123-5129
8. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648
9. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J (1999) Cleavage of the HER2 ectodomain is a pervanadate activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59: 1196-1201
10. Corbett IP, Henry JA, Angus B, Watchorn CJ, Wilkinson L, Hennessy C, Gullick WJ, Tuzi NL, May FE, Westley BR, Horne CHW (1990) NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 161: 15-25
11. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC (2004) HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22: 854-863
12. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC (2001) Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7: 2703-2711
13. Kwong KY, Hung MC (1998) A novel splice variant of HER2 with increased transformation activity. Mol Carcinog 23: 62-68
14. Luftner D, Schnabel S, Possinger K (1999) c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy. Int J Biol Markers 14: 55-59
15. Mass RD, Press M, Anderson S, Murphy M, Slahon D (2001) Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol 20: 22a (abstr 85)
16. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
17. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749
18. Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, Albanell J, Keenan EJ, Lluch A, Garcia-Conde J, Baselga J, Clinton GM (2002) NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8: 347-353
19. Montemurro F, Choa G, Faggiuolo R, Donadio M, Minischetti M, Durando A, Capaldi A, Vietti-Ramus G, Alabiso O, Aglietta M (2004a) A phase II study of three-weekly docetaxel and weekly Trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 66: 38-45
20. Montemurro F, Valabrega G, Aglietta M (2004b) Trastuzumab-based combination therapy for breast cancer. Exp Opin Pharmacother 5: 81-96
21. Pauletti G, Godolphin W, Press MF, Slamon DJ (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63-72
22. Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G (2003) Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology 43: 354-362
23. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182
24. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712
25. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792
26. Tokuda Y, Ohnishi Y, Shimamura K, Iwasawa M, Yoshimura M, Ueyama Y, Tamaoki N, Tajima T, Mitomi T (1996) In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 73: 1362-1365
27. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726
28. Wilson EB (1927) Probable inference, the law of succession, and statistical inference. J Am Statist Assoc 22: 209-212
29. Zhang H, Wang Q, Montone KT, Peavey JE, Drebin JA, Greene MI, Murali R (1999) Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Exp Mol Pathol 67: 15-25